Ascentage Pharma Group International (AAPG) Cash & Equivalents (2022 - 2024)

Historic Cash & Equivalents for Ascentage Pharma Group International (AAPG) over the last 3 years, with Q4 2024 value amounting to $124.3 million.

  • Ascentage Pharma Group International's Cash & Equivalents fell 1376.01% to $124.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $124.3 million, marking a year-over-year decrease of 1376.01%. This contributed to the annual value of $122.4 million for FY2024, which is 1396.37% down from last year.
  • According to the latest figures from Q4 2024, Ascentage Pharma Group International's Cash & Equivalents is $124.3 million, which was down 1376.01% from $144.2 million recorded in Q4 2023.
  • In the past 5 years, Ascentage Pharma Group International's Cash & Equivalents registered a high of $189.2 million during Q4 2022, and its lowest value of $124.3 million during Q4 2024.
  • In the last 3 years, Ascentage Pharma Group International's Cash & Equivalents had a median value of $144.2 million in 2023 and averaged $152.6 million.
  • In the last 5 years, Ascentage Pharma Group International's Cash & Equivalents tumbled by 2380.02% in 2023 and then tumbled by 1376.01% in 2024.
  • Over the past 3 years, Ascentage Pharma Group International's Cash & Equivalents (Quarter) stood at $189.2 million in 2022, then fell by 23.8% to $144.2 million in 2023, then fell by 13.76% to $124.3 million in 2024.
  • Its Cash & Equivalents was $124.3 million in Q4 2024, compared to $144.2 million in Q4 2023 and $189.2 million in Q4 2022.